Top Tech Companies (2,070)
Don't see your company?
Create a company profile
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson’s disease, endometriosis* and uterine fibroids* , as well as clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. Review our Community Guidelines: https://bit.ly/3L8M8hx *in collaboration with AbbVie
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
At Seer, we develop innovative solutions that act as a gateway to the proteome. Our goal is to empower the scientific community with tools to achieve exceptional scientific outcomes. We do this by removing the technological barriers that stand between breakthrough ideas and the information that can make them a reality. Over the last 15 years, the fields of genomics and transcriptomics have undergone an explosion in content and discovery, fueled by massively parallel technologies that made large-scale studies possible and tractable. Advancement in those fields have deepened our understanding of biology and ushered in new treatment mechanisms and diagnostics solutions that impact everyday human life. Similar capabilities have evaded the field of proteomics. As a result, researchers have been forced into a tradeoff: the scale of the study, or the depth of its coverage. Until now. We’re committed to eliminating the obstacles that have kept proteomics’ potential from matching the pace of advancements we’ve seen in other fields. We believe that unbiased, deep, rapid, large-scale proteomics can, and must, become accessible to the broad scientific community so that we may significantly advance our understanding of biology, health, and disease. And those studies will require solutions that allow us to accurately survey and analyze the full diversity of proteins across individuals, over time.
Founded in 2007, Scimitar sought to fill a void in the life sciences industries. Scimitar founders realized that life sciences companies were relatively early in their operational maturity when compared to long established product development, manufacturing, and supply chain industries such as automotive or consumer goods. Scimitar Inc. brings best practices and innovative solutions to life sciences organizations via cutting-edge consulting in a collaborative effort to increase client profits and reinvestment in life-saving research, ultimately to improve well-being of patients everywhere. From research through commercial, Scimitar drives operational transformations and strategic initiatives across the drug product lifecycle. Our expertise is multi-dimensional: Strategy Development Strategy Realization Program Management Strategic Sourcing Governance Organizational Design Post-Merger Integration Risk Management Change Management Performance Measurement Scimitar serves our industry-leading clients by providing only experienced, capable consultants, who have demonstrated success across a large number of client engagements. Scimitar is unique relative to other consulting firms in that we… §…focus exclusively on clients, not internal projects and marketing efforts §…work together with your people, not around, behind, or above them §…do not rely on client projects to “train” our consultants §…do not operate under a pyramid structure, sparing you expensive partner premiums
Exact Sciences is changing the way we think about detecting and treating cancer. As a leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.
_0.jpg)
OneStudyTeam, a member of the Reify Health family, provides the cloud-based platform StudyTeam to accelerate the development of new and life-saving therapies. StudyTeam brings research site workflows online and enables sites, sponsors, and other key stakeholders to work together more effectively using common technology. The suite of StudyTeam solutions reduces site burden and helps sites pre-screen and enroll more patients, provides sponsors with end-to-end visibility into recruitment activity across all channels, and guides sites in conducting the trial for patients who have been enrolled. StudyTeam is trusted by the largest global biopharmaceutical companies, used in over 5,000 research sites, and is available in over 100 countries. One mission. One team. That’s OneStudyTeam
.jpg)
Lightship is your complete solution for decentralized clinical trials. We built our virtual-first clinical trial model from the ground up, allowing patients to participate in clinical trials from the comfort of home. Come join the team perfecting the way clinical trials are done!
Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit, multispecialty academic medical center that integrates clinical and hospital care with research and education. Founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation, Cleveland Clinic has become one of the largest and most respected hospitals in the country. Cleveland Clinic facilities can be found throughout Northeast Ohio, as well as around the country and world including: Cleveland Clinic Florida Cleveland Clinic Canada Cleveland Clinic Abu Dhabi Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas Cleveland Clinic health system includes eight regional hospitals, 16 family health centers, a children's hospital for rehabilitation and one affiliate hospital. Cleveland Clinic is accredited by The Joint Commission, the nation’s largest accreditor of healthcare organizations. Our family health centers offer: Outpatient care Primary care Numerous subspecialties Numerous locations All of our hospitals, family health centers, outpatient clinics and home healthcare programs are also accredited by The Joint Commission under its hospital accreditation program.
NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company's technology enables a wide variety of basic research and translational medicine applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody technology platform is particularly well suited for developing T cell engagers, receptor cross-linking agonists, targeted cytokines, and target neutralizers. Our lead product candidate, Imvotamab, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, and it is currently in two Phase 2 clinical trials for the treatment of relapsed and/or refractory diffuse large B cell lymphoma and follicular lymphoma. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with relapsed and/or refractory solid and hematologic malignancies, and it is currently in a Phase 1 clinical trial. Also in our product pipeline is IGM-7354 and IGM-2644. IGM-7354 is an anti-PD-L1 IgM antibody that targets the delivery of interleukin-15 (IL-15) cytokines to the area of PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis has the capability to solve the global organ crisis by providing an alternative to allotransplantation. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing both the key virology and immunology hurdles that have impeded its advancement to date and provide commercially-viable products to save and enhance the lives of patients in need.
Intelliject, a specialty pharmaceutical company, develops combination drug products empowering patients to control their medical conditions.
Bioreactors and operating systems for the industrial production of cultivated meat
At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine.
Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. We are developing a modular and high-performing DNA sequencing platform that will deliver high-quality data, increase workflow flexibility, and make next-generation sequencing technology more accessible. Our proprietary approach to improving the signal-to-noise ratio allows us to provide groundbreaking innovations in surface chemistry, instrumentation, and biochemistry to drastically decrease run costs and capital costs while delivering high sequencing data quality.
Synthego is a genome engineering company enabling the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. By vertically integrating hardware, software, bioinformatics, chemistry, and molecular biology, Synthego is at the forefront of innovation advancing the next generation of medicines through providing access to genome editing at an unprecedented scale. //// Our Culture of Diversity: Different Faces from Different Places At Synthego, our differences make us unique, help us innovate, and allow us to persevere. We stand firmly behind our values, strive to achieve representation, and celebrate diversity in perspectives and backgrounds. We welcome all team members to be their best selves as we move forward towards fulfilling our shared vision of revolutionizing genome engineering technology to help make biological therapies accessible to all patients.
DEKA is one of the leading research and development companies in the country and is the birthplace of some of the most innovative and life-changing products of our time. For over thirty years, DEKA Research & Development Corp. has made Manchester, New Hampshire home. Located about an hour from Boston, the beach, and the mountains, we are situated in the beautiful and historic Amoskeag Millyard buildings located in downtown Manchester. DEKA continues to be a place where no idea seems too big and where creativity and crazy cool gizmos reign supreme. The engineers, technicians, machinists, designers and all of the other folks who make up DEKA are some of the most creative and innovative professionals you could ever hope to meet. It's a place where one crazy idea can end up being the next greatest invention. At DEKA we embrace the spirit of innovation and constantly aim to turn the impossible into a reality. DEKA is filled with people who are driven to be among the best and brightest in their field of work. It’s a concentrated bunch of really smart thinkers, doers and problems solvers, who are driven to using innovative design solutions and state-of-the-art technology to improve lives. We all see endless possibilities in the power of technology to do good. Employees have the opportunity to work on diverse projects that have a positive, enduring impact on millions of people worldwide. We are growing! We're always seeking passionate individuals to join our growing team of evolved thinkers.
Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to help improve the lives of as many people as possible. With transformative technologies informed by massive amounts of big data, we are revolutionizing healthcare to provide physicians and patients with the highest quality information about their disease – from detecting it early and determining how best to treat it, to developing the next wave of novel therapies.
Tarsus is a late clinical-stage biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients with unmet needs.
